scispace - formally typeset
P

Priyanka Shah

Researcher at Central Drug Research Institute

Publications -  19
Citations -  435

Priyanka Shah is an academic researcher from Central Drug Research Institute. The author has contributed to research in topics: Docking (molecular) & Quantitative structure–activity relationship. The author has an hindex of 12, co-authored 19 publications receiving 378 citations.

Papers
More filters
Journal ArticleDOI

Interaction of a ruthenium(II)–chalcone complex with double stranded DNA: Spectroscopic, molecular docking and nuclease properties

TL;DR: In this paper, the interaction of a well characterized new complex 1 cis,fac-[RuCl(dmso-S)3(L)] LH = 1-(2-hydroxyphenyl)-3-(4-chlorophenyl) propenone with Calf-thymus DNA (CT-DNA) is monitored using UV-vis titration and ethidium bromide displacement studies.
Journal ArticleDOI

Synthesis of hybrid 4-anilinoquinoline triazines as potent antimalarial agents, their in silico modeling and bioevaluation as Plasmodium falciparumtransketolase and β-hematin inhibitors

TL;DR: Analogues of a novel class of hybrid 4-anilinoquinoline triazines synthesized with the aim of identifying the compounds with improved antimalarial activity preserving the potency of parent drug chloroquine reveal that the molecules are also good inhibitors of the enzyme P. falciparumtransketolase.
Journal ArticleDOI

Interaction between sulphur mobilisation proteins SufB and SufC: evidence for an iron-sulphur cluster biogenesis pathway in the apicoplast of Plasmodium falciparum.

TL;DR: The ATPase activity of recombinant P. falciparum nuclear-encoded SufC and its localisation in the apicoplast is demonstrated, suggesting the evolution of specialised functions in the plastid counterparts.
Journal ArticleDOI

Synthesis, molecular modeling and bio-evaluation of cycloalkyl fused 2-aminopyrimidines as antitubercular and antidiabetic agents

TL;DR: In silico docking studies indicate that mycobacterial dihydrofolate reductase is the possible target of these compounds, and opens a new gate to synthesize antitubercular agents for diabetic TB patients.
Journal ArticleDOI

Discovery of a new class of HMG-CoA reductase inhibitor from Polyalthia longifolia as potential lipid lowering agent.

TL;DR: The in vivo effects of 1 corroborated well with its molecular docking analysis and also with its hamster plasma pharmacokinetics, indicating a new structural class of HMG-CoA reductase inhibitor.